Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months

The purpose of this study is to explore the changes in metabolic parameters in patients treated with escitalopram for six months for major depression, generalized anxiety disorder or panic disorder, with or without agoraphobia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Major Depression Anxiety Disorders Depressive Disorder Depressive Disorder, Major Generalized Anxiety Disorder Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Mental Disorders Metabolic Diseases Metabolic Syndrome Mood Disorders Nutritional and Metabolic Diseases Panic Disorder

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Changi General Hospital

Singapore, 529889

About this study

This is an open-label study, with 4 scheduled visits. Recruitment of 100 subjects. Assessments include demographics, diagnosis, smoking frequency, Clinical Global Scale (CGI-S), weight, height,blood pressure, waist and hip circumference and fasting blood glucose and lipd profile.

Statistical analysis will be exploratory and mainly descriptive.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Give informed consent
Requires pharmacological treatment with escitalopram for major depression, generalized anxiety disorder or panic disorder
Aged 21 years old and above
Able to comprehend and comply with protocol
Not pregnant and if of child-bearing age, using adequate methods of contraception

Exclusion criteria

Currently taking or has taken in previous 3 months, any other antidepressants, antipsychotics, mood stabilizers, weight loss or lipid-profile modifying drugs
Contraindications to escitalopram
Unstable medical illness and/or is already under treatment of diabetes, hypertension, dyslipidemia, ischemic heart disease
History of non-response to escitalopram
Meets IDF definition of metabolic syndrome
Significant risk of suicide
Primary diagnosis or comorbid diagnosis of psychotic disorder, bipolar disorder, substance dependence and/or dementia

Sponsors and collaborators

Lead sponsor

Changi General Hospital

Other

Registry information

Official study title

Open-label Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months

Important dates

Study start: 2008
Primary completion: 2010
Study completion: 2010
First posted: Jul 9, 2008
Registry last updated: Jun 17, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed